Discover a clinically predictive and reproducible platform developed by The Jackson Laboratory for simultaneous efficacy and safety assessment. This platform identifies patient-therapy combinations at risk of developing severe inflammatory syndrome, a potentially fatal complication. Optimise the safety profiles of your immunomodulatory therapeutics before first-in-human trials by leveraging this platform.

In this bispecific case study, learn how the platform: 

• Captured donor-specific responses and their impact on efficacy and safety profiles
• Identified potential toxicity risks 
• Correlated cytokine release and tumour growth inhibition in the context of bispecifics

Seize this opportunity to gain valuable insights into the future of efficient preclinical drug discovery and development.

Brought to you by